Form 4: Tharimmune Director Kelly Anderson Acquires 6,300 Shares Under Equity Incentive Plan

Sentiment:

Insider Transaction Report


Tharimmune, Inc. Director Kelly Anderson reported the acquisition of 6,300 shares of common stock on June 23, 2025, as part of the company's 2023 Omnibus Equity Incentive Plan.

Summary

  • Reporting Person: Kelly Anderson, a Director of Tharimmune, Inc. (THAR).
  • Transaction Type: Acquisition of common stock.
  • Shares Acquired: 6,300 shares.
  • Transaction Date: June 23, 2025.
  • Acquisition Price: $0 per share, indicating a grant or award.
  • Source of Acquisition: Tharimmune, Inc. 2023 Omnibus Equity Incentive Plan.
  • Post-Transaction Ownership: Kelly Anderson directly holds 6,300 shares of common stock.

Sentiment

Score: 7

Explanation: The acquisition of shares by a director, even as a grant, generally indicates alignment of interests with shareholders and confidence in the company's long-term performance.

Positives

  • Director Kelly Anderson acquired 6,300 shares of common stock, aligning her interests with shareholders.
  • The acquisition was part of the 2023 Omnibus Equity Incentive Plan, indicating a structured compensation or incentive program for management.

Future Outlook

The document does not contain any forward-looking statements or guidance regarding future performance or strategic direction.

Management Comments

  • Director Kelly Anderson acquired 6,300 shares of common stock pursuant to the Tharimmune, Inc. 2023 Omnibus Equity Incentive Plan.

Industry Context

This Form 4 filing is a standard disclosure for insider transactions, reflecting a director's acquisition of company stock. Such transactions are common across industries as part of executive and director compensation plans designed to align management interests with shareholder value.

Corporate Governance

Change TypeDescriptionEffective DateImpact Assessment
Equity Incentive Plan UtilizationCommon stock was issued under the Tharimmune, Inc. 2023 Omnibus Equity Incentive Plan, which is a standard corporate governance mechanism for employee and director compensation.06/23/2025This indicates the company is utilizing its approved equity compensation plans to incentivize directors, aligning their interests with long-term shareholder value.

Related Party Transactions

  • Acquisition of common stock by Director Kelly Anderson from Tharimmune, Inc. as part of the 2023 Omnibus Equity Incentive Plan.

Stakeholder Impact

  • Shareholders: Potential positive signal due to director's increased stake, aligning interests with long-term company performance.
  • Employees: The utilization of the 2023 Omnibus Equity Incentive Plan benefits participants, including directors, as part of their compensation structure.

Key Dates

DateDescription
06/23/2025Date of acquisition of 6,300 shares of common stock by Director Kelly Anderson.
07/07/2025Signature date of the Form 4 filing by Kelly Anderson.

Recommendation

hold

Keywords

Tharimmune, THAR, Form 4, insider transaction, beneficial ownership, equity incentive plan, director, stock acquisition

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.